Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**G-CSF mobilized donor lymphocytes** are lymphocyte (T cell, B cell, NK cell) populations collected from donors after administration of granulocyte colony-stimulating factor (G-CSF). G-CSF is given to healthy donors to stimulate the release and mobilization of hematopoietic stem and progenitor cells, as well as various immunocompetent lymphocyte subsets, into peripheral blood. The donation (usually by leukapheresis) contains lymphocytes with altered function and cytokine profiles compared to conventionally collected donor lymphocytes. G-CSF induces shifts toward Th2 immune responses, increases naive and regulatory T cell subsets, and may modulate the risk and severity of graft-versus-host disease (GVHD) after allogeneic transplantation. G-CSF-mobilized donor lymphocytes are used in hematopoietic stem cell transplantation settings, particularly for donor lymphocyte infusion (DLI) to treat relapse or incomplete engraftment after allogeneic transplant[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on G-CSF mobilized donor lymphocytes.